Pancreatic ductal adenocarcinoma remains one of oncology's most intractable challenges precisely because KRAS mutations — present in over 90% of cases — have historically been undruggable. The emergence of RAS(ON) inhibitors like daraxonrasib represents a genuine therapeutic inflection point, making understanding their failure modes arguably as important as the initial efficacy signal.
This Nature Medicine study applied circulating tumor DNA (ctDNA) surveillance to 44 patients enrolled in a phase 1/2 trial of daraxonrasib, mapping the genomic landscape of acquired resistance as it evolved in real time. Rather than relying solely on tissue biopsies, the liquid biopsy approach captured emerging resistance mutations with temporal resolution that conventional sampling cannot match. Complementary preclinical translational modeling — spanning cell lines and in vivo systems — then stress-tested those resistance mechanisms and systematically evaluated combination regimens capable of intercepting them.
The findings position daraxonrasib resistance not as a dead end but as a tractable problem with identifiable bypass pathways, several of which point toward specific combination partners that preclinical data suggest could meaningfully delay or prevent resistance emergence. This analytical framework — sequencing resistance first, then designing combinations — is methodologically significant beyond pancreatic cancer.
In broader context, the RAS inhibitor field has learned hard lessons from KRAS G12C-selective agents like sotorasib and adagrasib, where resistance via KRAS amplification, secondary mutations, and RTK reactivation emerged rapidly in lung cancer. Daraxonrasib's multi-selective RAS(ON) profile was designed partly to preempt some of those escape routes, making the specific resistance mechanisms identified here scientifically informative about which pathways remain plastic. The 44-patient cohort is modest, and preclinical modeling necessarily simplifies tumor ecosystem complexity. Nonetheless, for a cancer where median survival rarely exceeds twelve months after metastatic diagnosis, this combination roadmap may represent the most actionable near-term translational advance the field has seen in years.